Jeffrey Weber, MD, PhD from the NYU Langone Medical Center, New York, NY discusses his talk on novel combination therapies for melanoma and future Phase II and III trials at the 2016 World Congress on Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria. Prof. Weber predicts that interesting data on Phase II and Phase III trials will be released in the next 2 to 3 years in which nivolumab or pembrolizumab have been combined with antagonistic antibodies like 4-1BB, OX40, LAG-3 or TIM3. Existing data is only available from Phase I trials so far which Prof. Weber presents on at WCCS/EADO 2016. Summarizing, Prof. Weber believes that the future for immunotherapy in melanoma looks bright.
Get great new content delivered to your inboxSign up